At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
FSGS First Trust SMID Growth Strength ETF
Market Closed 12-12 16:00:00 EST
31.18
+0.00
0.00%
盘后31.18
+0.000.00%
16:04 EST
High31.18Low31.18Vol285.00
Open31.18D1 Closing31.18Amplitude0.00%
Mkt Cap31.18MTradable Cap31.18MTotal Shares1.00M
T/O8.86KT/O Rate0.03%Tradable Shares1.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Akebia Announces Establishment of Rare Kidney Disease Pipeline
GlobeNewswire  ·  12-01
Akebia Announces Establishment of Rare Kidney Disease Pipeline
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
GlobeNewswire  ·  11-20
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
Dimerix Achieves Positive IDMC Review for Phase 3 FSGS Trial
TIPRANKS  ·  11-19
Dimerix Achieves Positive IDMC Review for Phase 3 FSGS Trial
A Look at Travere Therapeutics’s Valuation Following Positive Phase 3 FILSPARI Data in FSGS
Simply Wall St.  ·  11-11
A Look at Travere Therapeutics’s Valuation Following Positive Phase 3 FILSPARI Data in FSGS
Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys
MT Newswires Live  ·  11-07
Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
GlobeNewswire  ·  11-05
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
GlobeNewswire  ·  10-30
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
GlobeNewswire  ·  10-22
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
GlobeNewswire  ·  10-17
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
Dimerix's Drug Candidate to Treat Kidney Disease Receives Orphan Drug Designation in Japan
MT Newswires Live  ·  09-30
Dimerix's Drug Candidate to Treat Kidney Disease Receives Orphan Drug Designation in Japan
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
GlobeNewswire  ·  09-03
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
Dimerix's Market Value Falls Despite Full Funding, Record Licensing Deal, Euroz Says
MT Newswires Live  ·  09-01
Dimerix's Market Value Falls Despite Full Funding, Record Licensing Deal, Euroz Says
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
Benzinga_recent_news  ·  08-29
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
GlobeNewswire  ·  08-13
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
GlobeNewswire  ·  07-31
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
GlobeNewswire  ·  07-08
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis

Introduction

Company Name.
First Trust SMID Growth Strength ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund will normally invest at least 90% of its net assets in the securities that comprise the index. The index is designed to select dividend-paying securities issued by small capitalization U.S. companies.
Issue price:
--